Hoofa Capsule contains Levocetirizine 5 mg and Montelukast 10 mg, combining an antihistamine and a leukotriene receptor antagonist to provide effective relief from allergic conditions. Levocetirizine, a selective H1 receptor antagonist, works by inhibiting the effects of histamine, thereby reducing symptoms such as sneezing, nasal congestion, rhinorrhea, and itching associated with allergic rhinitis and chronic urticaria. Montelukast selectively blocks leukotriene D4 receptors in the lungs and bronchial tubes, preventing bronchoconstriction and inflammation, which makes it beneficial in managing asthma and allergic rhinitis. The synergistic action of these two agents helps in controlling both immediate and delayed allergic responses, improving patient outcomes in allergic airway diseases. Hoofa Capsule is indicated for the treatment of seasonal and perennial allergic rhinitis, chronic idiopathic urticaria, and as adjunctive therapy in asthma management. It is generally well tolerated; common adverse effects may include headache, fatigue, dry mouth, and gastrointestinal disturbances. Caution is advised in patients with hepatic or renal impairment, and it is recommended to use under medical supervision. Hoofa Capsule should be taken as prescribed, usually once daily, to achieve optimal therapeutic benefits.